VERU - Veru Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Veru Inc.

48 NW 25th Street
Suite 102
Miami, FL 33127
United States
305-509-6897
http://www.verupharma.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees171

Key Executives

NameTitlePayExercisedYear Born
Dr. Mitchell S. Steiner M.D., F.A.C.SChairman, Pres & CEO509.05kN/A1961
Dr. Harry FischVice Chairman & Chief Corp. Officer217.4kN/A1959
Ms. Michele GrecoCFO, Exec. VP of Fin. & Chief Admin. Officer360.9kN/A1959
Dr. K. Gary Barnette Ph.D.Chief Scientific Officer76.12kN/A1968
Philip GreenbergExec. VP of Legal & Sec.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Veru Inc., an oncology and urology biopharmaceutical company, engages in developing medicines for prostate cancer treatment and prostate cancer supportive care, and urology specialty pharmaceuticals. The company's commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections; and PREBOOST* 4% benzocaine WIPES for the prevention of premature ejaculation. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist, planned Phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN*, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its customers primarily include international agencies, non-government organizations, and ministries of health and other governmental agencies, which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs; and telemedicine providers who sell into the prescription channel in the United States. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida with offices in London, United Kingdom and Kuala Lumpur, Malaysia.

Corporate Governance

Veru Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.